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As of 2010, the worldwide economic impact of dementia was estimated at $604
billion USD; and without discovery of a cure or effective interventions to delay disease
progression, dementia’s annual global economic impact is expected to surpass $1 trillion
USD as early as 2030. Alzheimer’s disease (AD) is the leading cause of dementia
accounting for over 75% of all cases. Toxic accumulation of amyloid beta (Aβ), either by
overproduction or some clearance failure, is thought to be an underlying mechanism of
the neuronal cell death characteristic of AD—though this amyloid hypothesis has been
increasingly challenged in recent years. A compelling alternative hypothesis points to
chronic neuroinflammation as a common root in late-life degenerative diseases including
AD. Apolipoprotein-E (APOE) genotype is the strongest genetic risk factor for AD: APOE-ε4
is proinflammatory and individuals with this genotype accumulate more Aβ, are at high risk
of developing AD, and almost half of all AD patients have at least one ε4 allele. Recent
studies suggest a bidirectional relationship exists between sleep and AD pathology. Sleep
may play an important role in Aβ clearance, and getting good quality sleep vs. poor quality
sleep might reduce the AD risk associated with neuroinflammation and the ε4 allele. Taken
together, these findings are particularly important given the sleep disruptions commonly
associated with AD and the increased burden disrupted sleep poses for AD caregivers. The
current review aims to: (1) identify individuals at high risk for dementia who may benefit
most from sleep interventions; (2) explore the role poor sleep quality plays in exacerbating
AD type dementia; (3) examine the science of sleep interventions to date; and (4) provide a
road map in pursuit of comprehensive sleep interventions, specifically targeted to promote
cognitive function and delay progression of dementia.
Keywords: circadian, sleep, chronotherapy, bright light therapy, aging, mild cognitive impairment, Alzheimer’s,
dementia
INTRODUCTION
The economic impact of dementia is staggering. As of 2010 the
annual cost of dementia worldwide was estimated at $604 billion
USD, equivalent to 1% of global gross domestic product (Wimo
and Prince, 2010). Dementia’s economic impact is composed of:
(1) direct medical care costs (e.g., clinic visits, drugs, and hospital
care); (2) direct social care costs (e.g., dementia support programs
and community services); and (3) indirect costs associated with
unpaid care (e.g., basic care, and instrumental activities of daily
living (ADL; Wimo and Prince, 2010). Indirect costs—$252 bil-
lion USD, contributing 42% of dementia’s economic impact—are
a heavy burden borne almost entirely by friends and family of peo-
ple living with dementia (Wimo and Prince, 2010). Dementia’s
drag on the global economy increases dramatically as a function
of disease severity: (1) the economic impact doubles as dementia
progresses from mild to severe; and (2) there is a four-fold
increase in cost for institutionalization compared to community
dwelling (Prince and Jackson, 2009). However, an aging popula-
tion is the greatest driver increasing dementia’s prevalence and
economic impact. Current projections estimate the number of
people living with dementia will reach 65.7 million by 2030 and
115.4 million by 2050 (Prince et al., 2013a). Without discovery
of a cure or development of effective interventions to prevent or
delay disease progression, dementia’s annual worldwide economic
impact is expected to surpass $1 trillion USD as early as 2030
(Wimo and Prince, 2010; Prince et al., 2013b).
Decades of dementia research have made two things abun-
dantly clear: (1) a cure is likely many years away; and (2) the
inescapable economic reality is that society desperately needs
interventions specifically targeting individuals at high risk for
dementia. Effective interventions could bridge the gap, decreasing
dementia’s economic burden, while buying time and conserving
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the resources necessary to develop a cure. To date, lifestyle
interventions to promote cognitive function in older adults at
risk for dementia have often focused on exercise (Liu-Ambrose
et al., 2010, 2012; Anderson-Hanley et al., 2012; Barnes et al.,
2013; Nagamatsu et al., 2013) or cognitive training (Basak et al.,
2008). However, recent findings (Lim et al., 2013) suggest sleep
quality plays a critical role in preserving cognitive function and
reducing the risk of dementia in individuals with a genetic
susceptibility to Alzheimer’s disease (AD)—the most common
cause of dementia. The importance of sleep for human health
and performance has long been well established empirically
(Van Dongen et al., 2003; Walker, 2008; McCoy and Strecker,
2011; Caruso, 2014), and yet sleep is typically the first sacrifice
made in order to meet the demands of daily schedules in a
24-h society, as articulated nicely in the book “Sleep: a very
short introduction” (Lockley and Foster, 2012). The growing
popularity of “energy drinks” may be reflective of a disturbing
societal trend toward increased sleep debt and heightened daytime
sleepiness. The current review aims to: (1) identify individuals
who are at high risk for dementia and who may benefit most
from sleep interventions; (2) explore the role poor sleep qual-
ity plays in exacerbating AD type dementia; (3) examine the
science of sleep interventions to date; and (4) provide a road
map in pursuit of comprehensive sleep interventions, specifically
targeted to promote cognitive function and delay progression of
dementia.
DEMENTIA: ALZHEIMER’S DISEASE AND APOE -GENOTYPE
Dementia, literally meaning devoid of the mind, is a clinical
syndrome characterized by a persistent and typically progressive
state of degraded cognitive function (e.g., learning, memory,
executive function and decision making) serious enough to
impair occupational or social functioning (Apostolova et al.,
2012). Dementia has numerous causes commonly classified as
either neurodegenerative (e.g., Alzheimer’s, Parkinsonian, or
Frontotemporal dementias) or non-degenerative (e.g., Vascular,
Multiple Sclerosis, or Alcoholic dementias) (Apostolova et al.,
2012). Alzheimer’s disease is by far the most common cause of
dementia, accounting for as many as 75% of all cases (Prince
and Jackson, 2009). It is the 5th leading cause of death in the
United States for adults 65 years or older (Thies and Bleiler,
2013). Alzheimer’s disease pathogenesis is thought to result
from synaptic failure as a function of interference in synaptic
transmission and ultimately synaptic loss (Marcello et al., 2008;
Nimmrich and Ebert, 2009; Selkoe, 2011). Historically, AD
pathology has been characterized by neuronal cell death and
brain atrophy—hallmarked by the accumulation and deposition
of amyloid plaques and neurofibrillary tangles (NFTs)—in limbic
and association cortices as well as related subcortical nuclei
(Selkoe, 2011). More recently, histopathological analysis of over
2300 postmortem brains ranging in age from 1–100 years suggests
AD has a much more nuanced and staged pathological process
than previously expected, with an extended preclinical period and
disease course that may span five or more decades (Braak et al.,
2011). If so, the window for targeted interventions to combat
AD progression may be much larger than previously imagined.
Clearly intervention early in the pre-clinical stages would be best.
THE AMYLOID HYPOTHESIS OF ALZHEIMER’S DISEASE
The discovery in 1984 of the amino acid sequence for amyloid-
beta (Aβ; Glenner and Wong, 1984b) and subsequent linking of
Aβ to AD (Glenner and Wong, 1984a) gave rise to the “amyloid
hypothesis”; which contends that AD results from toxic accumu-
lation of Aβ, either by overproduction or some clearance failure,
altering membrane protein function and interfering with synap-
tic transmission, ultimately causing neuronal cell death (Tanzi
and Bertram, 2005; Selkoe, 2011, 2013). The amyloid hypothesis
gained credence with the discovery that the apolipoprotein E
(APOE) genotype is the strongest genetic risk factor for AD (for
reviews see Kim et al., 2009; Holtzman et al., 2012). Apolipopro-
tein E is a polymorphic gene—with three common alleles (ε2,
ε3, and ε4)—that plays a central role in lipid metabolism and
transport as well as cholesterol absorption from the intestine
(for reviews see Seripa et al., 2011; Egert et al., 2012). Individ-
uals with the APOE-ε4 allele are predisposed to accumulate Aβ
(Castellano et al., 2011) and are at significantly higher AD risk
(Poirier et al., 1993; Strittmatter et al., 1993), whereas the ε2
allele is protective against AD (Corder et al., 1994). Recently, a
meta-analysis pooled data collected from over 27,000 patients in
33 countries, and examined prevalence of the ε4 allele among
patients diagnosed with AD (Ward et al., 2012b). Their findings
indicate that 48.7% of AD patients have at least one ε4 allele,
while 9.6% are homozygous-ε4/ε4. In addition to increasing AD
risk, the APOE-ε4 genotype likely plays a role in accelerating AD
onset (Roses, 1996). Age has long been considered the greatest
AD risk factor: after the age of 65, prevalence and incidence of
AD doubles with each 5-year increment in age (Jorm and Jolley,
1998; Brookmeyer et al., 2007; Prince et al., 2013a). Interest-
ingly, the ε4 population distribution provides a genetic basis for
variance in age of AD onset, as evidenced by an analysis of AD
age of onset as a function of APOE genotype: the mean age of
onset varies from less than 70 years for ε4/ε4 to over 90 years for
ε3/ε2 (Roses, 1996). Taken together, these findings establish the
importance of APOE genotype in AD and appear to provide a
compelling case for the amyloid hypothesis.
The ε4 allele is associated not only with increased AD risk, but
also increased plasma levels of cholesterol (Ehnholm et al., 1986;
Boerwinkle et al., 1987; Fenili and McLaurin, 2005), as well as
higher rates of cardiovascular disease (Song et al., 2004; Anoop
et al., 2010) and stroke (Kalaria, 2001; Szolnoki and Melegh,
2006). Furthermore, the ε4 allele amplifies AD risk associated
with diabetes. For example type 2 diabetes mellitus (T2DM) is
a known independent risk factor that almost doubles a person’s
AD risk (Peila et al., 2002), but that risk escalates even further in
individuals with T2DM and the ε4 allele; specifically, individuals
with both T2DM and the ε4 allele are more than 5 times more
likely to develop AD than people with neither risk factor (Peila
et al., 2002). In addition, the ε4 allele alters brain response to acute
injury following insults such as hemorrhagic stroke, exacerbating
neuronal injury and hindering repair processes (Tang et al., 2003;
Lanterna and Biroli, 2009). Given the risks associated with the
ε4 allele, one might expect this allele to have been selected out
or at least be rare and yet prevalence of the APOE-ε4 genotype
for most of the world’s ethnicities falls between 10–20%, with a
range of 6–40% (Corbo and Scacchi, 1999; Singh et al., 2006).
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By itself the ε4 allele does not doom one to certain death by
AD or vascular disease, nor does the accumulation of plaques
and tangles lead to dementia in all cases. Post mortem analyses of
brains have uncovered many cases in which AD type plaques and
tangles are present without the expected deficits in cognitive func-
tion (Davis et al., 1999; Price et al., 2009; Balasubramanian et al.,
2012). Conversely, in studies of very old adults—individuals 80 to
100+ years old—up to 50% of dementias previously diagnosed
as AD were later determined to be of unknown etiology (i.e.,
postmortem analysis failed to identify brain pathology typical of
AD or other dementias; Crystal et al., 2000; Imhof et al., 2007;
Middleton et al., 2011). So now, almost three decades after the
birth of the amyloid hypothesis, it would seem that deposition of
Aβ plaques is neither necessary nor sufficient to produce dementia
characteristic of AD. Indeed it now appears that when compared
with Aβ pathology, severity of NFT pathology—specifically in the
neocortex—is more predictive of the extent of cognitive impair-
ment. Neurofibrillary tangles have traditionally been considered
downstream from Aβ plaque deposition; however, recent evi-
dence suggests NFT precursors take place long before Aβ plaque
deposition (Braak et al., 2011). In light of these findings, the
amyloid hypothesis has been increasingly challenged in recent
years (Reitz, 2012; Balin and Hudson, 2014; Drachman, 2014). For
example, a compelling alternative hypothesis suggests late-onset
AD is the result of chronic inflammatory conditions linking AD
with vascular disease of small blood vessels in the brain—induced
by oxidative inflammation and dysregulated amyloid metabolism
(Marchesi, 2011; Krstic and Knuesel, 2013). A neuroinflammatory
perspective of AD is discussed in the next section.
Critics of the amyloid hypothesis see Aβ plaques and NFTs
as markers of AD, downstream in the disease process but not
the root cause; whereas proponents of the amyloid hypothesis
point to theoretical constructs such as “cognitive reserve” (i.e.,
a conceptual framework accounting for individual differences
in capacity to withstand neural insults such as brain injury or
pathology (Stern, 2009)) and other genetic, lifestyle, or environ-
mental factors that may serve to moderate one’s AD risk. These
moderators are thought to include: protective genotypes (e.g.,
APOE-ε2 (Corder et al., 1994; Tanzi and Bertram, 2005)), good
sleep quality (Lim et al., 2013), cardiovascular health, education,
and other hallmarks of a healthy lifestyle such as life-long learn-
ing, exercise and eating well (Imtiaz et al., 2014). The underly-
ing mechanisms by which these moderators preserve cognitive
function—despite accumulation of plaques and tangles normally
associated with AD—have yet to be fully explained. It is clear,
however, that individuals with the APOE-ε4 genotype are at high
risk for AD type dementia, and may represent an ideal target for
interventions.
THE NEUROINFLAMMATORY PERSPECTIVE OF ALZHEIMER’S DISEASE
An alternative to the classic amyloid centric view of AD sug-
gests that late-onset AD results from age-related alterations in
innate immunity and chronic systemic inflammation (for review
see Krstic and Knuesel, 2013). According to this perspective, a
persistent inflammatory state leads to dysregulation of clearance
mechanisms of misfolded or damaged neuronal proteins, and
to tau-associated impairments of axonal integrity and transport
(Krstic and Knuesel, 2013). In line with this perspective, grow-
ing evidence points to Aβ plaques as a downstream conse-
quence of prior changes—possibly related to chronic systemic
inflammation—leading to neuronal and synaptic losses (for
review see Drachman, 2014). Importantly, accumulation of Aβ
plaques and NFTs are widely recognized as proinflammatory
processes (Finch, 2011). Thus, it is possible that these hallmarks
of AD pathology originate from chronic systemic inflammation—
as a function of aging combined with proinflammatory genetic
and lifestyle factors (for review see Watt, 2014)—but then serve to
exacerbate neuroinflammation and thereby accelerate AD onset
and progression. As such, accumulation and/or the clearance
failure of Aβ plaques and NFTs may be more related to chronic
inflammation than previously recognized (Krstic and Knuesel,
2013; François et al., 2014).
Indeed, evidence is growing in support of a neuroinflam-
matory perspective of AD—which acknowledges amyloid as a
critical component in the disease process—but sees much of
the damage in AD to be better associated with the effects of
chronic inflammation (for review see Akiyama et al., 2000).
Interestingly, most of the polymorphisms conferring increased
late-onset AD risk are located in genes of the innate immune
system (Harold et al., 2009; Lambert et al., 2009). An intriguing
alternative explanation for increased AD risk associated with the
APOE-ε4 allele is that it is the most proinflammatory APOE
allele. Furthermore, it appears that chronic systemic inflamma-
tion may provide a common underlying link connecting many
AD risk factors (i.e., APOE genotype, cardiovascular disease,
T2DM, poor diet, poor sleep quality, and a sedentary lifestyle)—
all of which may be considered proinflammatory factors (Watt,
2014).
SLEEP IN NORMAL AGING AND ALZHEIMER’S DISEASE
Sleep changes as a function of normal aging both in terms of
decreased quality and quantity (for reviews see Espiritu, 2008;
Crowley, 2011). Sleep complaints are common in older adults:
more than 55% of adults 65 years or older have at least one
chronic sleep complaint (Foley et al., 1995). The most common
being an inability to stay asleep at night, followed closely by
chronic complaints of excessive daytime sleepiness, resulting in
frequent daytime naps (Foley et al., 1995). These complaints,
in particular the reports of excessive daytime sleepiness (a key
indicator of accumulated sleep debt (Carskadon et al., 1986;
Johns, 1991)), suggest that age-related changes in sleep are likely
the result of something beyond reduced need for sleep. If age-
related changes in sleep were simply the result of reduced need,
then why would the majority of older adults complain about
decreased quality and quantity of their sleep? Whether these
changes in sleep should even be considered “normal” is well
worthy of debate, but for the purposes of this review, suffice it
to say sleep is often disrupted as a function of seemingly normal
aging.
By comparison, sleep disruptions in AD are exaggerated to the
point that they could be characterized as a form of accelerated
or hyper-aging: sleep disruptions in adults with AD are similar
in nature to those observed in age-matched adults without AD,
but tend to be more extreme and progress faster (for review see
Frontiers in Aging Neuroscience www.frontiersin.org December 2014 | Volume 6 | Article 325 | 3
Landry and Liu-Ambrose Sleep interventions for mild cognitive impairment
Bliwise, 1993). Nighttime sleep in AD is repeatedly interrupted by
bouts of restlessness and active periods of wakefulness; whereas
daytime activity is routinely broken up by sleep intrusions (Satlin
et al., 1995). As AD progresses, day and night become increasingly
difficult to distinguish in terms of behavioral sleep-wake rhythms
(as measured by actigraphy; van Someren et al., 1996; Hatfield
et al., 2004; Fetveit and Bjorvatn, 2006). For older adults with
moderate to severe AD, extreme disruption of the sleep-wake
rhythm is typical; to the extent that their disrupted sleep signif-
icantly increases the burden on family members and caregivers
(McCurry et al., 1999)—an important topic that will be discussed
at length in a later section.
SLEEP MECHANISMS
To better understand the nature of sleep disruptions in aging
and AD, a brief review of the biology that drives sleep-wake
rhythms is instructive (Dijk and Czeisler, 1995; Mistlberger, 2005;
Beersma and Gordijn, 2007; Chokroverty and Avidan, 2012).
There are two distinct mechanisms that determine sleep need,
the timing of sleep onset, and sleep duration (Daan et al., 1984;
Borbély et al., 1989): (1) a homeostatic recovery process that
increases sleep need as a simple function of prior wakefulness;
and (2) a circadian mechanism (i.e., ∼24 h biological clock, see
Moore, 2013) that coordinates physiology and behavior with the
solar day-night cycle (for review see Golombek and Rosenstein,
2010). The homeostatic recovery process is gated by the cir-
cadian mechanism (Daan et al., 1984), which thereby extends
and consolidates physiological states (i.e., sleep or wakefulness).
Beyond its role in gating the homeostatic sleep drive, the circadian
mechanism actively drives both states—sleep and wake—in order
to coordinate physiology and behavior with the solar cycle (for
review see Mistlberger, 2005). This process of synchronizing
internal physiology and behavior with the solar cycle is called
entrainment.
In humans, the net result of these combined mechanisms is a
biphasic diurnal sleep-wake rhythm synchronized with the 24 h
solar cycle—meaning the ∼24 h rhythm is normally composed
of a single wake phase of ∼16 h, with the majority of activity
occurring during the day; and a single sleep phase of∼8 h at night
(Beersma and Gordijn, 2007). The circadian “clock” consolidates
sleep and wake states in part by driving two “zones” or gates of
behavioral state that oppose the homeostatic mechanism (Lavie,
1986; Dijk and Czeisler, 1995): (1) a wake maintenance zone
that occurs 2–3 h prior to habitual sleep onset—a time when
homeostasis drives hard for sleep due to the extended duration of
prior wakefulness; and (2) a sleep maintenance zone that occurs
roughly 2–3 h prior to habitual wake onset—when several hours
of prior sleep have drained the homeostatic sleep drive (Strogatz
et al., 1986; Dijk and Czeisler, 1995). By delaying sleep onset
in the early evening, the wake maintenance zone intensifies the
homeostatic sleep drive such that when this zone ends and the
circadian sleep gate opens, the transition from wake to sleep is
very rapid (typically within 10–20 min; Carskadon et al., 1986).
Conversely, in the early morning—after several hours of sleep
have drained the homeostatic sleep drive—the circadian clock
boosts sleep drive to extend the sleep phase and maximize sleep
efficiency (i.e., the time spent actually asleep vs. time spent in
bed between sleep and wake states). This sleep maintenance
zone occurs at the nadir of the daily body temperature rhythm
(Tb-min: the lowest point in the core body temperature rhythm,
which typically occurs ∼2–3 h prior to habitual activity onset)
and the peak of rapid-eye movement (REM) sleep (Dijk and
Czeisler, 1995), which is important for consolidation of learning
and memory (Walker and Stickgold, 2004; Stickgold, 2005).
Circadian gating of the homeostatic recovery sleep process is
an elegant solution to the fragmentation of sleep-wake rhythms
that would otherwise occur if homeostasis alone were to deter-
mine sleep drive. As such, age-related circadian dysregulation and
impaired circadian gating of the homeostatic sleep drive could
explain disrupted sleep-wake rhythms typically observed in older
adults (Münch et al., 2005; Cajochen et al., 2006).
CIRCADIAN RHYTHMS AND SLEEP IN NORMAL AGING
A detailed survey of circadian rhythms and aging is beyond
the scope of the current review; however age-related changes of
the circadian system have been well characterized elsewhere (for
reviews see Monk and Kupfer, 2000; Touitou and Haus, 2000;
Weinert, 2000; Hofman and Swaab, 2006; Farajnia et al., 2014). In
short summary, the suprachiasmatic nucleus (SCN; a bilateral set
of hypothalamic neurons situated above the optic chiasm) serves
as the biological clock; and much like other areas of the brain, the
SCN is vulnerable to the aging process (Touitou and Haus, 2000;
Hofman and Swaab, 2006). Age-dependent changes in the human
SCN include decreased volume and cell number (Swaab et al.,
1985; Hofman, 1997), decreased amplitude and disrupted output
signaling (i.e., peptide expression (Hofman and Swaab, 1994)),
and decreased sensitivity to input signals such as light (i.e., for
moderate light intensity (Duffy et al., 2007) but not bright light
(Benloucif et al., 2006)).
Age-related change in light sensitivity is particularly important
since light is the primary stimulus the SCN uses to coordinate
physiology and behavior with the solar cycle (Monk and Kupfer,
2000; Weinert, 2000). As such, age-dependent changes of the
circadian system and weakened circadian signaling likely play
a prominent role in the fragmentation of sleep-wake rhythms
observed in older adults. For example, early awakenings and
the inability to sustain sleep through the early morning hours
may be the result of impaired functioning of the circadian
sleep maintenance zone. Timing of the sleep maintenance zone
is synchronized with Tb-min (∼4:00 am for individuals who
usually wake-up ∼7:00 am). In young-middle aged adults this
zone is associated with extreme propensity for sleep and it is
typically difficult to wake people at this point of their sleep phase
(Lavie, 1986). Furthermore, even when they are awakened, most
people find it very easy to fall back to sleep during the sleep
maintenance zone. By contrast, arousal thresholds in older adults
are much lower around Tb-min and once awakened, older adults
may have more difficulty falling back to sleep after their Tb-min
(Phillips and Ancoli-Israel, 2001). However, the latter point is not
without controversy given findings that suggest older adults wake
up more often than younger adults, but are able to fall asleep at
the same rate (Klerman et al., 2004).
Another age-related sleep characteristic is the tendency for
older adults to go to bed earlier than they did when they
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were younger (based on self-report measures (Roenneberg et al.,
2007)). On average, older adults go to bed ∼2 h earlier than
younger adults relative to clock time (Roenneberg et al., 2007)—
which could correspond with the circadian wake maintenance
zone (Lavie, 1986); however assessments comparing circadian
phase of sleep-onset are necessary to confirm this possibility.
Nonetheless, quantitative assessment of wake maintenance zone
strength has confirmed age-dependent weakening (Münch et al.,
2005): compared with young adults (20–31 years), older adults
(57–74 years) sleep significantly more during the wake main-
tenance zone and report higher subjective sleepiness ratings in
the late afternoon and evening (Münch et al., 2005). Excessive
daytime sleepiness—the second most common chronic sleep
complaint in older adults—could also be explained by impaired
functioning of the circadian daytime arousal/wakefulness signal
(Mistlberger, 2005). As such, it seems likely that typical sleep
disruptions in older adults are due to age-related changes in the
circadian system, resulting in greater homeostatic influence on
sleep drive. Therefore, interventions targeting enhanced function-
ing of circadian gated wake-maintenance and sleep-maintenance
zones may be an effective strategy to improve sleep quality in older
adults.
CIRCADIAN RHYTHMS AND SLEEP IN ALZHEIMER’S DISEASE
Sleep disruptions in AD are exaggerated in a way that implies
a form of accelerated or hyper-aging (Witting et al., 1990). The
fragmentation of sleep-wake rhythms in AD patients is more
similar to much older adults without AD than age-matched adults
without AD. This notion of hyper-aging in AD is supported
by analysis of SCN atrophy in AD vs. non-AD (Swaab et al.,
1985; Zhou et al., 1995; Stopa et al., 1999). Antibody-staining
of arginine-vasopressin (AVP) expressing SCN neurons shows
age-dependent decreases in volume and cell number; however
SCN atrophy doubles in age-matched adults with AD vs. non-
AD (Swaab et al., 1985). Importantly, in discussing this study’s
findings, the authors point out that the 50% reduction in AVP-
expressing SCN cells—observed in adults with AD—matches the
lesion magnitude required to disrupt circadian rhythms in rodent
studies (Van den Pol and Powley, 1979; Pickard and Turek, 1983).
Arginine-vasopressin (AVP) mRNA expression in the human
SCN provides additional evidence that sleep disruptions in AD
are likely caused in part by changes within the SCN (Liu et al.,
2000). This study showed AVP mRNA expression is three times
lower in AD patients than controls matched for age and time of
death. So to summarize the science to date, it is clear that sleep
is disrupted in normal aging, these disruptions are exaggerated
in AD, and that circadian dysregulation is likely an underlying
mechanism of disrupted sleep-wake rhythms in both normal
aging and AD. These findings raise an important question: are
age-related changes in sleep-wake rhythms clinically relevant to
AD, beyond the inconvenience, discomfort, or frustration these
disruptions may cause patients and caregivers?
GETTING QUALITY SLEEP IS CRITICAL FOR OLDER ADULTS
AT RISK FOR ALZHEIMER’S DISEASE
In this section the case is made for sleep quality as a critical
determinant of AD risk and progression in older adults. The
FIGURE 1 | A simplified schematic of the proposed pathways
associated with AD pathogenesis. The red arrows indicate possible
pathways whereby circadian dysregulation and poor sleep might promote
AD pathogenesis through proinflammatory mechanisms and increased
accumulation and deposition of Aβ. According to this model, bidirectional
relationships exist between circadian dysregulation and poor sleep;
inflammation and Aβ deposition; and AD pathogenesis and circadian
dysregulation.
case is based on compelling evidence supporting the following
assertions: (1) poor sleep quality is predictive of cognitive decline
in older adults; (2) good sleep quality may protect against genetic
susceptibility factors for AD, perhaps by increasing Aβ clearance
from the brain; and (3) poor sleep quality is proinflammatory
and associated with increased risk of developing metabolic and/or
cardiovascular diseases, known to be independent risk factors for
AD (see Figure 1 for a schematic outlining proposed pathways
whereby circadian dysregulation and poor sleep are associated
with AD pathogenesis). The importance of addressing sleep
quality in the early stages of AD is emphasized not only from the
patient’s perspective, but also as a means of reducing caregiver
burden in an effort to delay the need for institutional care.
SLEEP IN ALZHEIMER’S DISEASE: IMPACT ON COGNITION AND HEALTH
Sleep is vital for optimal health and well-being. Prolonged
accumulation of sleep debt impairs physical, mental, and emo-
tional fitness and can cause behavioral and mood disorders
(Chokroverty and Avidan, 2012). The proinflammatory aspects
of chronic sleep restriction are well documented (for reviews see
Irwin, 2002; Faraut et al., 2012). Of particular importance to
people at risk for AD, some sleep characteristics are predictive
of cognitive decline in older adults, such as excessive daytime
sleepiness, frequent awakenings, and nighttime sleep durations
less than 6.5 h (Foley et al., 2001; Jaussent et al., 2012; Keage
et al., 2012). Given how critical sleep is for cognitive function,
it makes intuitive sense that sleep is an important factor in AD
patient outcomes. However, the directionality of the relationship
between sleep and AD has not always been clear. While it is
generally accepted that sleep disruptions increase as a function
of AD severity (Prinz et al., 1982a,b; Vitiello et al., 1990)—due
at least in part to AD-related neuropathology of the circadian
system (for review see Coogan et al., 2013)—the role disrupted
sleep plays in AD onset and progression has yet to be fully
appreciated.
Does disrupted sleep somehow cause or accelerate AD? Two
recent studies have shed light on this issue: the first provides
new evidence showing good sleep quality may be protective
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for individuals genetically susceptible to AD (Lim et al., 2013);
while the second uncovers an underlying mechanism that might
explain how sleep could protect against the formation of AD
neuropathology (Xie et al., 2013). The first study, a 6 year lon-
gitudinal study of 698 community dwelling older adults without
dementia, examined the relationship between sleep consolidation,
cognitive function, AD incidence, and the development of Aβ
and NFT pathology (as determined by post-mortem analysis of
201 participants who died during the study). Importantly, their
analysis included comparisons for persons carrying the ε4- vs. ε4+
APOE genotypes. The results indicated better sleep consolidation
(as measured by actigraphic sleep recordings comparing “good”
vs. “poor” sleepers: 90th vs. 10th percentile, respectively) signifi-
cantly attenuated the AD risk associated with the ε4+ genotype.
Specifically, among ε4+ genotypes, better sleep consolidation
was significantly associated with lower 6 year incidence rates
of cognitive decline and NFT densities, but not Aβ pathology.
In the second study, brain imaging of live mice was used to
show interstitial space within the brain increases by as much as
60% during sleep, allowing for increased convective exchange of
cerebrospinal fluid (CSF) with interstitial fluid (Xie et al., 2013).
This increased CSF fluid exchange was also shown to significantly
increase Aβ clearance during sleep. Taken together, these studies
suggest a bidirectional relationship may exist between sleep and
AD pathology, see Ju et al. (2014). As such, sleep disruptions
characteristic of AD may involve a form of mutually destructive
reinforcement whereby circadian-related sleep disruptions con-
tribute directly to onset and progression of AD neuropathology,
while at the same time AD neuropathology exacerbates circadian
dysregulation of sleep-wake rhythms. In addition to these direct
effects, poor sleep quality may increase AD risk indirectly as a
moderator of other AD risk factors.
As mentioned earlier T2DM is an independent risk factor for
AD and other dementias (Peila et al., 2002; Crane et al., 2013),
particularly among individuals with the APOE-ε4 genotype (Peila
et al., 2002). This increased risk is linked to cognitive deficits
associated with impaired glycemic control in T2DM (Cukierman-
Yaffe et al., 2009). Over the last decade, compelling evidence
has identified disrupted sleep as an independent T2DM risk
factor (Gottlieb et al., 2005; Knutson et al., 2006, 2007; Laposky
et al., 2008; Gale et al., 2011; Touma and Pannain, 2011; Wan
Mahmood et al., 2013), contributing to diabetes progression
(Gale et al., 2011) and severity (Knutson et al., 2007). Poor
sleep quality (as measured by the Pittsburgh Sleep Quality Index;
PSQI) is predictive of higher levels of hemoglobin-A1c (HbA1c;
Knutson et al., 2007; Wan Mahmood et al., 2013), which is the
gold standard for indexing glycemic control and diabetes self-
management (Canadian Diabetes Association Clinical Practice
Guidelines Expert Committee, 2013).
Vascular disease is another well-known AD risk factor
(Breteler, 2000; Kivipelto et al., 2006; Brown and Thore, 2011;
Debette et al., 2011; Virta et al., 2013). In fact, some critics
of the amyloid hypothesis have argued in favor of a “vascular
hypothesis” as the genesis of AD (de la Torre, 2010; Marchesi,
2011; Drachman, 2014). This alternative hypothesis suggests that
AD type dementia results from damage to small blood ves-
sels, caused by oxidative-induced inflammation and dysregulated
amyloid metabolism (Marchesi, 2011). As with T2DM, circadian
dysregulation and resultant disruption of sleep-wake rhythms are
independent risk factors for vascular disease (Brown et al., 2009;
Eguchi et al., 2010; Ruiter Petrov et al., 2014) (for reviews, see
Cappuccio et al., 2011; Palma et al., 2013). Thus in addition to the
direct effects described earlier, circadian dysregulation and resul-
tant sleep disruptions may increase AD risk indirectly as well by
increasing one’s risk of developing T2DM and/or vascular disease.
Consequently, for older adults at high AD risk—based on genetic
susceptibility or other known risk factors—disrupted sleep should
not simply be dismissed as a normal part of aging. Age-related
changes in sleep are common; however, for individuals susceptible
to AD, poor sleep quality may be a critical contributing factor
increasing AD risk, progression and severity.
It is worth repeating here that a neuroinflammatory perspec-
tive of AD is compelling in that all of these well-established AD
risk factors (poor sleep quality, T2DM, and vascular disease) have
inflammation in common (see Finch, 2011; Watt, 2014). As such
combating increased inflammation—as function of aging (i.e.,
“inflammaging”; Franceschi et al., 2007) and proinflammatory
lifestyle factors (i.e., poor diet, limited exercise, and poor sleep
quality; Watt, 2014)—is an intriguing target for future interven-
tions to delay AD onset and progression.
SLEEP IN ALZHEIMER’S DISEASE: CAREGIVER BURDEN
Beyond the impact poor sleep may have on AD risk, addressing
sleep quality in individuals with dementia is critical from the per-
spective of caregivers: Disrupted behavioral sleep-wake rhythms
among AD patients typically result in sleep disruptions for their
caregivers, which significantly increases caregiver burden and is
a deciding factor in transitioning from community dwelling to
institutional care. The majority of care for people with dementia
is provided by family members (Prince and Jackson, 2009). Most
family caregivers are women, typically wives of the demented and
as such many are 65 years of age or older (Stone et al., 1987). In
one study examining sleep disturbances in AD, 63% of spousal
caregivers reported their sleep was disrupted by their demented
spouse (Creese et al., 2008). A recent study has confirmed high
prevalence of disrupted sleep among AD caregivers, though the
rate was lower: 45% (Cupidi et al., 2012).
The sleep disturbances among caregivers are significantly
more severe than the age-related sleep disruptions observed
in age-matched controls (Wilcox and King, 1999). One study
showed on average spousal caregivers sleep less than 6 h/night
(McKibbin et al., 2005), which as discussed earlier is predic-
tive of cognitive decline. In fact, there is evidence of cognitive
deficits associated with caregiver status (i.e., AD spousal care-
givers vs. age-matched non-caregivers) (Caswell et al., 2003).
Caswell et al. (2003) showed that the variance in Digit Symbol
Substitution test scores was explained by age, education, and
caregiver status (i.e., AD caregivers scored significantly worse than
non-caregivers).
In addition to cognitive impairment, sleep disruptions in
AD caregivers is associated with poorer mental health (Willette-
Murphy et al., 2006), decreased quality of life (QoL; Cupidi
et al., 2012), and significantly increased caregiver burden (Alle-
gri et al., 2006; Cupidi et al., 2012; Kamiya et al., 2014). The
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latter is of particular importance because caregiver burden is the
strongest predictor of self-rated health in dementia caregivers
(Abdollahpour et al., 2014). Most importantly—in terms of the
economic impact of AD—disturbed sleep and its impact on
burden of care is a primary trigger in the decision to transition
from community dwelling to institutional care (Sanford, 1975;
Pollak and Perlick, 1991; Gold et al., 1995). Findings from Sanford
(1975) emphasized the importance of addressing sleep disrup-
tions in AD: in their survey of family members who had recently
placed their demented relative in an extended care facility, 84%
said they would take their relative back if the sleep disturbances
could be remedied.
To summarize briefly, addressing sleep quality in older adults
at risk for AD is of profound importance because disrupted sleep
is associated with: (1) increased AD risk through direct and indi-
rect pathways; (2) increased AD severity both in terms of cognitive
symptoms and neuropathology; (3) accelerated AD progression;
(4) negative impacts on sleep, cognitive function, health, and
QoL of AD caregivers; and as a result (5) dramatically increased
caregiver burden—so much so that disrupted sleep is often cited
as a primary trigger when families decide to institutionalize their
demented relative. Therefore, the need to address sleep quality in
AD patients and their caregivers is compelling. Whether or not
sleep disturbances in AD can be addressed is, however, very much
an unanswered question.
CANWE IMPROVE SLEEP IN AGING AND ALZHEIMER’S
DISEASE?
Having characterized how sleep changes as a function of normal
aging and AD, and given the severity of sleep disruptions asso-
ciated with AD, the obvious questions that follow are: (1) Can
these age-related changes be prevented in normal aging?; and (2)
Can sleep quality—as defined both in terms of sleep duration and
consolidation—be improved in older adults with AD? Put simply,
the science to date is at best undecided; however there may yet
be untapped potential in interventions aimed at improved sleep
hygiene and enhanced circadian regulation. The following section
discusses sleep hygiene and circadian regulation, exploring how
they might provide the key to improving sleep in older adults.
While interventions aimed at improving sleep might benefit older
adults in general, we focus mainly on older adults with—or at
high risk for—AD because of the particular importance sleep
quality plays in the health outcomes of patients with AD. The
sections that follow discuss a number of tools that may prove
useful in addressing age-related sleep disruptions.
SLEEP HYGIENE
Sleep hygiene refers to a set of behavioral practices that can impact
sleep quality, such that poor sleep hygiene could exacerbate or
even cause poor sleep; and conversely, good sleep hygiene should
result in feeling more rested and alert upon awakening, as well as
a greater ability to function throughout the day—while experi-
encing less of the cognitive drag associated with excessive daytime
sleepiness (Stepanski and Wyatt, 2003; Lockley and Foster, 2012;
American Academy of Sleep Medicine, 2014). Poor sleep hygiene
in AD patients is symptomatic of the disorder in the sense that
they nap excessively during the day and get up often at night.
Whereas a single nap during the afternoon—not exceeding 2 h—
may be helpful both in terms of alleviating sleep debt and promot-
ing cognition (Taub, 1979; Tamaki et al., 1999; Campbell et al.,
2005), advocates of good sleep hygiene caution that excessive
daytime napping likely worsens age-related sleep complaints (i.e.,
shortened duration and fragmentation of subsequent nighttime
sleep; Hays et al., 1996; Stepanski and Wyatt, 2003; American
Academy of Sleep Medicine, 2014).
The science to date is unclear on the degree to which efforts to
improve sleep hygiene affect sleep quality and quantity in normal
aging or AD. It may be that people with difficulty sleeping have
already done what they are willing to do in terms of addressing
their sleep hygiene. Or perhaps older adults have come to accept
changes in their sleep as an inevitable part of aging, and thus have
not considered the importance of good sleep hygiene. Regardless,
given how critical getting quality sleep is for older adults at risk
for dementia, further empirical studies are warranted to: (1)
determine whether lifestyle interventions specifically designed for
this population can improve sleep hygiene; and if so (2) determine
whether better sleep hygiene translates to increased quality of
sleep.
EFFECTS OF LIGHT ON CIRCADIAN RHYTHMS AND SLEEP
In comparison to the effects of sleep hygiene on sleep quality, the
impact of light on circadian regulation and sleep-wake rhythms
is much better understood. Light is the primary time cue our
biological clock uses to entrain physiology and behavior with the
solar day-night cycle. As such, exposure to light (even low-level
light from lamps and electronic devices) can change the timing of
circadian rhythms. These changes in circadian timing are called
phase shifts. Much like we can adjust our watches forward or
backward when traveling to a new time zone; light can shift
our biological clock forward (i.e., phase advance) or backward
(i.e., phase delay). The effect of light on circadian rhythms is
time-dependent, meaning the magnitude and direction of phase
shifts depend on the timing of light exposure relative to Tb-min.
A phase response curve (PRC) is a graphical representation of
stimulus effect (i.e., magnitude of the phase shift) plotted as a
function of the time the stimulus is applied, typically in relation
to Tb-min.
The time-dependent phase shifting effects of light have been
well characterized elsewhere (Czeisler et al., 1989; Khalsa et al.,
2003; Revell et al., 2012; St Hilaire et al., 2012; Rüger et al.,
2013). In summary, phase delays result from exposure to light at
night before Tb-min—when we would normally be sleeping, well
after the time our biological clock is expecting light. Conversely,
circadian rhythms are phase advanced by early morning light
exposure following Tb-min. Thus, in terms of human circadian
sleep-wake rhythms: (1) light at night before Tb-min delays the
rhythm, resulting in a later sleep-onset and a later wake-onset the
following morning (assuming the absence of other factors such
as an alarm clock); and (2) early morning light shortly after Tb-
min advances the rhythm such that subsequent sleep and wake
onsets occur earlier than they did prior to the light exposure.
The magnitude of a light-induced phase shift is greatest in the
hours immediately prior to Tb-min (delays) and following Tb-
min (advances) (Dawson et al., 1993).
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In addition to time-dependence, several factors influence the
magnitude of light-induced phase shifts including light dura-
tion, intensity, and color (Khalsa et al., 2003; Revell et al.,
2012; St Hilaire et al., 2012; Rüger et al., 2013). In general,
magnitude increases with increased duration and/or intensity,
and full-spectrum “white” light works best; however, short-
wavelength “blue” light (450–500 nm) has been shown to be
nearly as effective as “white” light (Revell et al., 2012; Rüger
et al., 2013). Bright light—when used in accordance with the
principles of the known PRC to light—is highly effective at
synchronizing circadian rhythms of physiology and behavior.
Beyond its role in synchronizing circadian rhythms, bright light
has well defined “alerting” effects that can combat sleepiness,
elevate mood, and improve cognitive function (Badia et al.,
1991; Cajochen et al., 2000; Plitnick et al., 2010; Münch et al.,
2012).
To date, bright light has been used successfully as a
non-pharmacological therapy to address a number of circadian
regulation related disorders including: (1) delayed sleep phase
onset in young adults (Gradisar et al., 2011; Saxvig et al., 2014);
(2) seasonal affective disorder (Glickman et al., 2006; Rastad et al.,
2008); (3) shiftwork induced internal desynchrony (Crowley et al.,
2003; Smith et al., 2009); (4) jet-lag (Forbes-Robertson et al.,
2012; Weingarten and Collop, 2013); and even (5) to address
sleep disruptions in nursing home residents (Kobayashi et al.,
2001; Fetveit et al., 2003; Alessi et al., 2005)—though there is
considerable variability in results with this population (as will be
discussed in detail later).
EFFECTS OF MELATONIN ON CIRCADIAN RHYTHMS AND SLEEP
Melatonin is a pineal gland produced hormone with modest
chronobiotic properties, though weak in comparison to circadian
phase-shifting effects of light (Arendt and Skene, 2005). How-
ever the PRC to melatonin is opposite that of light, such that
oral administration at night—before Tb-min—causes advances;
and melatonin in the morning—after Tb-min—delays circadian
rhythms (Lewy et al., 1998). The timing of pineal melatonin
production is controlled by the SCN—with low levels produced
during the day, rising levels ∼2 h before habitual sleep-onset,
and peak levels at night in advance of Tb-min (Arendt and
Skene, 2005; Burgess and Fogg, 2008). Melatonin is thought to be
involved in initiating sleep-onset because: (1) timing of the mela-
tonin rise coincides with opening of the circadian sleep gate; (2)
this rise in melatonin level is associated with increased sleepiness
and lowered core body temperature; (3) oral melatonin admin-
istration during the day has soporific effects; and (4) disrupted
sleep at night is sometimes associated with decreased amplitude
of melatonin during the sleep phase (Dijk and Cajochen, 1997;
Arendt and Skene, 2005; Pandi-Perumal et al., 2005).
Given its chronobiotic properties, melatonin is often used in
combination with bright light to address circadian regulation
related disorders (Crowley et al., 2003; Saxvig et al., 2014). Mela-
tonin is particularly useful as a chronobiotic for blind people
who lack the ability to use light to synchronize their physi-
ology and behavior to a desired work/social schedule (Skene
and Arendt, 2007). When taken daily—at an appropriate time—
oral melatonin administration in blind people reverses circadian
desynchrony, improves nighttime sleep, and reduces daytime
napping (Skene and Arendt, 2007).
EFFECTS OF EXERCISE ON CIRCADIAN RHYTHMS AND SLEEP
The chronobiotic properties of exercise have been well estab-
lished in various animal models (typically using wheel running
in rodents; for reviews see Mrosovsky, 1996; Hastings et al.,
1998). Whether or not exercise has chronobiotic properties in
humans is difficult to determine given the challenges associated
with isolating the effect of exercise vs. other factors such as light,
food, and social influences (for reviews see Mistlberger and Skene,
2004, 2005). However studies in blind people who lack sensi-
tivity to light—but remain able to entrain to daily work/social
schedules without using exogenous melatonin—suggest that non-
photic stimuli are capable of synchronizing circadian rhythms
(reviewed in Mistlberger and Skene, 2005). Whether it is exercise,
social influences, food (i.e., regularly scheduled mealtimes) or a
combination of all of these that provides the critical entrainment
signal is yet to be defined empirically.
Nonetheless, sufficient data exists from studies examining the
phase-shifting effects of exercise to produce an exercise/non-
photic PRC in humans (Mistlberger and Skene, 2005). In general
the results indicate that: (1) exercise in the evening before habitual
sleep-onset advances circadian rhythms; (2) exercise during the
habitual sleep time delays circadian rhythms; (3) the exercise PRC
in humans is consistent with ones reported in animal models;
(4) the PRC to exercise is sufficiently different from that of
light to diminish concerns of light as a confound; and (5) in
humans the phase-shifting effects of exercise are significant but
modest in magnitude, when compared to light or melatonin. The
effects of exercise on sleep quality, however, may be of greater
consequence.
Exercise has long been thought to play a role in the qual-
ity of sleep. Epidemiological studies examining the relationship
between exercise and sleep (see reviews Driver and Taylor, 2000;
Youngstedt, 2005) consistently show that: (1) when asked an
open ended question about behaviors that promote better sleep,
exercise is listed as the most important; and (2) based on self-
report data, people who exercise more also report having better
quality sleep and reduced daytime sleepiness, compared with
individuals who are more sedentary. These studies can only reveal
relationships, of course, and countless variables could explain the
correlation between exercise and sleep quality, including general
health and well-being and many other life-style factors. As such,
controlled experiments are important to determine the effects
of acute and chronic exercise on sleep (Driver and Taylor, 2000;
Youngstedt, 2005).
A meta-analytic examination of the empirical literature on
acute exercise and sleep (Youngstedt et al., 1997) suggests that:
(1) acute exercise increases total sleep time (TST) and alters sleep
architecture (i.e., increased slow wave sleep; SWS; and decreased
REM sleep); (2) exercise increases REM-onset latency, which may
explain the decrease in REM sleep duration (i.e., an exercise-
induced increase in SWS may delay REM-onset and thereby
decrease REM duration)—note that perhaps a REM rebound
would be seen in subsequent sleep bouts as has been shown
during multi-night electroencephalogram (EEG) recordings of
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recovery sleep following sleep deprivation (reviewed in Bonnet,
2000); (3) exercise improves sleep consolidation as determined
by decreased wake time after sleep-onset (WASO: time spent
awake after sleep onset, a measure of sleep fragmentation—
the inverse of sleep consolidation); (4) duration of exercise
moderates the effect of exercise on sleep, with effects requir-
ing durations of at least an hour; and (5) the magnitude of
exercise effects on sleep are modest and time dependent, with
greatest effects seen when exercise occurs 4–8 h prior to sleep-
onset. Note however, that the majority of studies have been
conducted on young, athletic, “good” sleepers—raising the pos-
sibility that the modest effects seen are the result of ceiling
effects.
Another potential explanation for the modest effect sizes
observed could be a simple function of the limited number of
electrodes typically used for EEG recordings of sleep. Interestingly,
a separate study showed location dependent increases in SWS
following a motor adaptation task (Huber et al., 2004). This
study used a 256-channel system for EEG recordings, providing
much greater spatial resolution. Their results indicate increases
in SWS were focused around the brain area involved in the
motor-adaptation task. Admittedly, 256-channel EEG record-
ings are impractical for regular use in sleep studies as they
make sleep uncomfortable. Our point is simply that failure to
detect large effects of exercise on EEG sleep recordings may in
part be a function of the measurement tools employed. Thus
it remains possible that exercise could have greater effect in
older adults who tend to be “poor” sleepers, and that these
effects may exist beyond our ability to detect important changes.
Indeed—with respect to the former—studies in older popu-
lations provide evidence supporting age as a moderator of
exercise effects on sleep (Driver and Taylor, 2000); but there
have been too few studies to date in older subjects, and the
data they provide typically relies on self-report measures of
sleep.
In recent years, however, exercise in older adults has become
the focus of important research on a separate, but related
topic. Exercise—as a promoter of cognitive function and neu-
ral plasticity—has become a promising line of inquiry both in
normal aging (Colcombe and Kramer, 2003; Colcombe et al.,
2004; Liu-Ambrose et al., 2010, 2012); and as an intervention
for older adults at risk for AD (Lautenschlager et al., 2008;
Baker et al., 2010; Nagamatsu et al., 2012, 2013). We mention
these studies in this section because sleep may play a role as
mediator or moderator of exercise-effects on cognitive function
in older adults. The impact of sleep on cognitive performance
is well known. Given the effect exercise has on sleep, it makes
intuitive sense that improved sleep—following exercise—could
be a factor in observed exercise effects on cognitive performance.
Interestingly, findings from a recent study suggest physical activity
can moderate the effects of poor sleep on executive function in
older adult women (Lambiase et al., 2014). Thus further study
is warranted to explore the mechanisms by which exercise, sleep,
and cognitive function are related—specifically in older adults.
In particular, studies are needed to explore potential synergistic
effects of interventions that combine exercise and improved sleep
quality.
EFFECTS OF FOOD ON CIRCADIAN RHYTHMS
Food has potent chronobiotic properties in animal models (for
reviews see Mistlberger, 1994; Stephan, 2002). However it is
not yet clear that food has the same effect on human circadian
rhythms; mainly because few properly controlled studies have
examined food-entrainment in humans (reviewed in Mistlberger
and Skene, 2005); and perhaps because for humans eating has
become somewhat of a social activity and we tend to eat more for
pleasure than to serve a metabolic need. Importantly, entrainment
to mealtime is SCN independent (i.e., SCN-lesioned animals can
synchronize circadian rhythms to a restricted feeding window;
Mistlberger, 1994; Stephan, 2002). While the properties of food-
entrainment have been well characterized, efforts to identify
the neural substrate of this SCN-independent mechanism have
not succeeded—despite decades of research and countless lesion
studies—suggesting that the chronobiotic properties of mealtime
are very robust and likely rely on a distributed system of multiple
redundant structures (Landry, 2013). A distributed system able
to withstand neural insults and injury makes intuitive sense,
given the survival importance of capacity to anticipate food
availability in a cyclical environment—at or near the top in terms
of the hierarchy of needs. Because SCN-atrophy is characteristic
of AD, regularly scheduled mealtimes might provide an SCN-
independent approach to enhance circadian regulation in older
adults with AD.
Indeed, food-entrainment as a means of enhancing circadian
regulation in AD is the subject of an interesting review (Kent,
2014). Note that while mealtimes in nursing homes are likely
already regularly scheduled, the amount of actual food intake that
occurs during these set mealtimes is likely highly variable. Thus
the use of food as a signal to enhance circadian regulation in AD
remains an intriguing possibility and well worthy of investiga-
tion for future studies. Particularly given evidence establishing
calorie restriction as an effective anti-aging intervention (see
Watt, 2014). Further support for examining food-entrainment as
an AD intervention comes from studies examining the adaptive
significance of APOE genotype. The distribution of APOE alleles
differs geographically (Singh et al., 2006), linked in some way to
diet and food availability (Corbo and Scacchi, 1999; Egert et al.,
2012): ε3 is more prevalent in populations with long-established
agricultural economies; whereas ε4 is most prevalent in areas
where foraging for food is still dominant and supply is limited
(Corbo and Scacchi, 1999). Evidence from studies in mice and
humans suggests the ε3 allele confers a selective advantage when
food supply is abundant—particularly for diets high in fat—
while ε4 may be more adaptive when food is scarce, due to its
increased efficiency in cholesterol extraction from foods (Corbo
and Scacchi, 1999; Egert et al., 2012). The transition from foraging
to an agricultural economy and increased longevity may explain
the shift in the population distribution of the APOE genotype
from ε4—considered the ancestral genotype (Egert et al., 2012)—
to predominantly ε3. Currently∼90% of the general population is
heterozygous-ε3 and∼60% are homozygous-ε3/ε3 (Roses, 1996).
Perhaps the increased AD risk associated with the ε4 allele is
reflective of evolutionary discordance (Konner, 2001), resulting
from a large divergence between the current proinflammatory
diets and lifestyles of Western societies and the original
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evolutionary environment in which our genetic makeup was
forged (see Watt, 2014 for more on this topic). If so, food
restriction may prove to be an important tool for improved
circadian regulation and combating inflammation in AD and
other diseases of aging.
THE RATIONALE AND SCIENCE TO DATE FOR
CHRONOTHERAPY IN OLDER ADULTS WITH ALZHEIMER’S
DISEASE
Given the nature and severity of sleep disruptions in AD, the
potential for disrupted sleep to exacerbate cognitive decline, and
its impact on caregiver burden; there is urgent need for inter-
ventions capable of improving sleep quality among older adults
with AD. Because sleep disruptions increase as a function of
AD severity—the result of AD-associated pathological changes in
the SCN—AD patients in residential care facilities tend to have
very poor circadian sleep-wake rhythms. These disruptions in
circadian regulation are probably exacerbated by the sedentary
lifestyle typical of residential care facilities—which leads to very
limited exposure to sunlight or any other form of bright light
(Campbell et al., 1988; Shochat et al., 2000). Thus, AD patients
in residential care are a particularly important target for sleep
interventions. Chronotherapy aims to enhance circadian regula-
tion of sleep-wake rhythms using appropriately timed exposure
to zeitgebers (i.e., German for “time giver”: time cues capable
of entraining circadian rhythms; e.g., light, melatonin, exercise,
and food). Because light is the most potent zeitgeber, it may
provide the best option for a chronotherapeutic intervention
designed to enhance circadian regulation and improve sleep
quality of AD patients in nursing homes. Bright light therapy
(i.e., application of full-spectrum bright light, specifically timed
in accordance with the human PRC to light; BLT) has been
shown to improve circadian regulation and sleep in community
dwelling older adults (Kohsaka et al., 1998; Kobayashi et al.,
1999) and older adults in nursing homes (Kobayashi et al.,
2001; Fetveit et al., 2003), leading to speculation the same may
be true for older adults with AD. However, these reports were
based on preliminary studies using very limited participant num-
bers and the effects were modest. Nonetheless randomized con-
trolled trials (RCTs) examining the efficacy of BLT to improve
circadian regulation and sleep in older adults with AD were
warranted.
BRIGHT LIGHT THERAPY IN OLDER ADULTS WITH DEMENTIA:
RANDOMIZED CONTROLLED TRIALS
Despite promising preliminary data early on from non-
randomized studies (Mishima et al., 1994; Fetveit et al., 2003)
and RCTs (Mishima et al., 1998; Lyketsos et al., 1999; Ancoli-
Israel et al., 2002), two Cochrane meta-analytic reviews of RCTs
testing light therapy in older adults with dementia have yielded
disappointing results (Forbes et al., 2009, 2014). The Cochrane
reviews included all RCTs of light therapy at any intensity and
duration testing effects on cognition, ADLs, sleep, challenging
behavior, and psychiatric symptoms associated with dementia
of any type. The updated Cochrane review published in 2014
examined 13 articles from 11 RCTs with a combined total of
499 participants and a drop-out rate of ∼20%. Their results
indicate light therapy had no significant effect on any of the
outcome measures, except for ADLs: a single RCT examined the
effect of light therapy on AD-related progressive decline of ADLs
(Riemersma-van der Lek et al., 2008)—this longitudinal study
(up to 3.5 years) reported whole-day bright light (∼1000 lux)
vs. dim light (∼300 lux) resulted in significant attenuation of
the gradual increase in functional limitations—a 53% reduction
in the slope of ADL limitations. Admittedly reductions in the
progression of ADLs is an important finding; but if light is such a
potent chronobiotic, then why are RCTs of light therapy yielding
such uninspiring results for other outcome measures? A close
examination of the methods employed by these studies reveals a
number of important factors that could explain the null findings
reported in the 2014 Cochrane review.
Limited sample size
Beyond the impact of having so few studies that met the inclusion
criteria for the Cochrane reviews (11 RCTs in total), the limited
number of participants recruited for the majority of these RCTs
probably hindered power to detect effects of light: 6/11 RCTs
had fewer than 34 participants combined across all conditions
(Mishima et al., 1998; Lyketsos et al., 1999; Graf et al., 2001;
Fontana Gasio et al., 2003; Dowling et al., 2008; Nowak, 2008);
and of the five remaining studies, only one had more than 34
participants assigned to an active light condition (Riemersma-van
der Lek et al., 2008).
Unknown circadian phase of Bright Light Therapy administration
The effect of light on circadian rhythms is time-dependent,
with greatest effect known to occur in the hours immediately
surrounding the Tb-min. For this reason, all of the studies that
defined the human photic PRC did so by timing light exposure in
relation to assessed circadian phase of the SCN—as determined by
Tb-min or measuring each participants dim light melatonin onset
(DLMO: a standard measure of circadian phase assessed by deter-
mining the onset of increased melatonin secretion—assayed in
saliva or blood—under dim light conditions because light expo-
sure suppress melatonin secretion (Pandi-Perumal et al., 2007)).
For practical reasons, all of the RCTs included in the Cochrane
review timed BLT in relation to clock time (i.e., a set time each
morning, afternoon, or evening) rather than by assessed circadian
phase of the participants. Given that circadian dysregulation is
symptomatic of dementia, it is very likely that circadian phase
varied significantly across participants. Therefore it is impossible
to know what circadian phase BLT was administered—which is
critical if one intends to address circadian dysregulation using
BLT. As such, failure to time BLT in relation to circadian phase
would dramatically increase variability of the outcome measures
and thereby hinder power to detect effects of light.
Insufficient light intensity
As is so for time-dependence, light intensity is a critical factor
determining the magnitude of effects on circadian regulation.
With two exceptions (Fontana Gasio et al., 2003; Riemersma-
van der Lek et al., 2008), all of the Cochrane RCTs used light
intensities that have been sufficient to shift circadian rhythms in
previous studies; however the vast majority of these studies (8/11)
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used light intensities at the mid-low range of known efficacy 5000
lux: (Mishima et al., 1998); 3000 lux: (Graf et al., 2001); 2500 lux:
(Ancoli-Israel et al., 2003; Dowling et al., 2005, 2008; McCurry
et al., 2011); 1000 lux:(Riemersma-van der Lek et al., 2008); and
a dawn-dusk simulator using ∼200 lux: (Fontana Gasio et al.,
2003). The intensity threshold for BLT-efficacy on circadian
regulation was tested primarily in healthy young adults; however
light perception varies significantly with age (note that the average
age of participants in the Cochrane RCTs was∼80). Furthermore,
evidence suggests sleep deprivation can attenuate light-induced
phase shifts—at least in an animal model (Mistlberger et al.,
1997)—and as discussed earlier sleep disruptions are common
in older adults. Therefore BLT in older adults, using lower light
intensities (i.e., <3000 lux) probably increases variability in
results, further diluting power to detect effects of light. In older
adults—to combat decreased light perception and attenuated
photic shifting—we suggest using brighter light intensity with
blue-enriched spectrum is best practice.
Insufficient light duration
We can apply a similar argument with respect to the typical
duration of BLT exposure used in the Cochrane RCTs. With only
one exception (Riemersma-van der Lek et al., 2008), all of the
Cochrane RCTs used 2 h or less of BLT exposure, which may work
perfectly well in young adults with intact circadian regulation, but
is likely significantly less effective in demented older adults with
compromised circadian systems.
Insufficient baseline data
With respect to actigraphic measures used to provide estimates of
sleep parameters—because of the highly variable nature of record-
ings in demented elderly which vary not only from night to night
but also week to week—baseline recordings of at least 14-days
are recommended (Van Someren, 2007). Unfortunately, the vast
majority of the Cochrane RCTs (9/11) used baseline recordings of
only 7-days or less, which has been shown insufficient to provide
acceptable reliability when estimating sleep parameters in elderly
demented (Van Someren, 2007).
Insufficient intervention duration
Given the advanced average age of participants (∼80 years)—
and the likelihood that for many of the participants circadian
dysregulation had progressed over the course of more than a
decade—it would seem plausible that reversing the process would
also take considerable time; and yet only one of the Cochrane
RCTs employed a longitudinal design using BLT for more than 6
months (Riemersma-van der Lek et al., 2008). Interestingly, this
is the study that reported a greater than 50% decline in the rate
of increased functional deficit in ADLs during BLT compared to
dim light controls. Furthermore, the authors reported progressive
improvements in sleep duration for the BLT condition, which
continued for the duration of the intervention (up to 3.5 years).
BRIGHT LIGHT THERAPY IN OLDER ADULTS WITH DEMENTIA: FURTHER
STUDY IS WARRANTED
Our intention in the previous section is not to cast aspersions on
what we believe to be important studies that aimed to define the
utility of BLT for a population in desperate need of intervention.
We hope only to place in proper perspective the findings from
the current Cochrane review. While we agree with the authors’
conclusion that there is an absence of evidence in favor of BLT
for use in elderly demented, there are sufficient methodologi-
cal shortcomings in these studies for us to urge caution when
interpreting their findings: absence of evidence is not evidence of
absence! This line of scientific inquiry is no doubt in its infancy,
and thus, we argue further study—using improved methods with
greater power to detect effects—is imperative.
That being said, we acknowledge the possibility that among
demented elderly, decades of progressive decline in circadian reg-
ulation may have rendered the system unresponsive to a singular
approach. Furthermore, dementia is a heterogeneous disease with
multiple etiologies, and thus, one-size-fits-all interventions are
likely doomed to fail. Combined interventions using all known
chronobiotics (i.e., light, melatonin, exercise, and food) may
be required to rescue circadian regulation in elderly demented;
and these combined interventions may only be effective for
specific types of dementia. Perhaps an even better approach is
to intervene before neurodegeneration has taken its toll on the
circadian system. Can we identify individuals at high risk for
dementia before the disease takes hold? Is there a prodromal stage
of AD during which circadian regulation can be preserved?
MILD COGNITIVE IMPAIRMENT
Identification of risk factors, combined with early diagnosis and
intervention, is best practice for any disease or disorder. However
as detailed in this review—for individuals with cognitive decline
on a trajectory toward dementia—early intervention may be even
more critical, at least with respect to preserving the quality of
their sleep. Sleep changes as a function of normal aging, but in
this population disrupted sleep may be particularly detrimen-
tal. Chronotherapy—targeting improved regulation of circadian
sleep-wake rhythms—will likely have greatest effect in the early
stages of dementia’s development; before neuropathology of the
circadian system has progressed to a point that renders the SCN
less responsive to entrainment cues. Fortunately over the last
two decades, early detection of a prodromal stage of dementia
has been the focus of intensive study. In the late 80’s, clini-
cians and researchers identified a state of cognitive deficit that
existed between normal aging and pathological decline (Reisberg
et al., 1988). Soon after, the theoretical construct “Mild Cognitive
Impairment” (MCI) was introduced as a clinical entity to capture
this gray zone of cognitive impairment—beyond what is expected
in normal aging but not severe enough to satisfy criteria for
dementia diagnosis (Petersen et al., 1999). Since then MCI has
evolved as a clinical entity. Its predictive utility for identify-
ing individuals with cognitive deficits that will later convert to
dementia diagnosis has become the subject of great debate and
controversy (for a detailed review of MCI and its evolution, see
Petersen et al., 2014). Here we provide a brief overview of the state
of the MCI science to date.
MILD COGNITIVE IMPAIRMENT: DEFINITION AND CLASSIFICATION
Much like dementia with its diverse etiologies, MCI is a het-
erogeneous entity whose definition has been refined several
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times over the last 20 years. As a diagnostic entity MCI is
broadly defined as cognitive impairment—based on a subjec-
tive complaint subsequently confirmed by objective cognitive
measures—not explained by normal aging and not severe enough
for dementia diagnosis (Petersen et al., 2014). Preserved inde-
pendence in functional abilities (as measured by ADLs) is a
key criterion that distinguishes MCI from dementia. Cognitive
impairment is defined as poor performance in one or more
of the following domains: executive functions, attention, lan-
guage, memory, and visuospatial skills. Mild cognitive impair-
ment is classified by domain of impairment beginning with
the memory domain: amnestic MCI (a-MCI) when memory is
impaired; and non-Amnestic MCI (na-MCI) when memory is
not impaired. Mild cognitive impairment is further classified by
number of domains impaired (i.e., single vs. multiple domain
MCI) (Petersen et al., 2014).
MILD COGNITIVE IMPAIRMENT: PREVALENCE, RISK FACTORS,
NEUROPATHOLOGY AND NEUROIMAGING
Using the current definitions—averaged across the major
population-based studies—worldwide prevalence of MCI and
a-MCI among adults over 65 years is 18.9% (Petersen et al.,
2014) and 7% (Ward et al., 2012a), respectively. That being
said, prevalence estimates vary greatly across studies highlighting
the need for enhanced standardization of operational definitions
of MCI and its various subtypes (Ward et al., 2012a). With
respect to risk factors, MCI is much the same as dementia: age,
education, APOE genotype, vascular disease, and diabetes have
all been identified (reviewed in Petersen et al., 2014). Results
for MCI studies vary between cross-sectional and prospective
studies; and as seen with risk factors associated with cognitive
decline in dementia—when compared with prospective studies—
cross-sectional studies consistently report stronger associations
for comorbidities such as vascular disease and diabetes (Petersen
et al., 2014). Whereas MCI can be defined on a continuum of
cognitive impairment distinct from normal aging and dementia;
efforts to define a profile of MCI-specific neuropathology have
been unsuccessful. A recent systematic review (Stephan et al.,
2012) examining 162 studies of MCI-associated neuropathology
concluded that MCI is heterogeneous and neuropathologically
complex, making identification of a definitive MCI profile prob-
lematic without systematic improvements in the science includ-
ing: representative brain tissue banks using standardized MCI
criteria; and standardized neuropathological protocols. Nonethe-
less, numerous pathological changes associated with MCI have
been identified including: (1) Aβ plaque and NFT formations;
(2) vascular pathologies; (3) neurochemical deficits; (4) cel-
lular injury; (5) inflammation; (6) oxidative stress; (7) mito-
chondrial changes; (8) changes in genomic activity; (9) synap-
tic dysfunction; (10) disturbed protein metabolism; and (11)
disrupted metabolic homeostasis (Stephan et al., 2012). Obvi-
ously neuropathology makes MCI distinct from normal aging,
but at present there is no clear demarcation in neuropathology
that defines the conversion from MCI to dementia. However—
in terms of identifying stages of decline—there may be hope
for the future given that at least preliminarily it seems neu-
ropathology associated with a-MCI may be more informative
than other MCI subtypes (Petersen et al., 2006; Stephan et al.,
2012).
MILD COGNITIVE IMPAIRMENT: CIRCADIAN RHYTHMS AND SLEEP
As MCI research progresses and refinements are made in iden-
tifying cohorts at greatest risk of near-term cognitive decline,
we will enhance our ability to target individuals who could
benefit most from interventions designed to promote—or at least
preserve—cognitive function. Because improved regulation of
circadian rhythms and sleep is critical in older adults with AD,
characterizing these parameters in older adults with MCI should
be a priority. Unfortunately, relative to the number of studies
examining sleep in normal aging and AD, there is a paucity of
studies characterizing sleep in MCI. However two studies have
provided valuable insight into the nature of circadian regulation
of sleep-wake rhythms in MCI (Naismith et al., 2014) and how
changes in circadian regulation may contribute to MCI and its
conversion to AD (Tranah et al., 2011). Naismith et al. (2014)
is the first MCI study to our knowledge that combined 14 day
sleep-wake actigraphy and polysomnographic (PSG) assessments
with melatonin sampling. Admittedly sample size was limited
(30 MCI vs. 28 age-matched controls), but their results indi-
cate significant differences associated with MCI: (1) the DLMO
is phase advanced in MCI compared to controls; (2) habitual
sleep-onset is significantly earlier in MCI vs. controls; (3) sleep
disruptions (defined by WASO using actigraphy) are signifi-
cantly higher in MCI vs. controls; and REM onset occurs later
in MCI vs. controls. These findings suggest circadian rhythms
and sleep in MCI are significantly different from age-matched
healthy controls, in a manner similar to the changes observed
in AD.
Interestingly, these MCI associated changes in melatonin onset
and habitual sleep-onset are consistent with disruption of the
circadian gated wake-maintenance zone discussed earlier. The
second noteworthy MCI study (Tranah et al., 2011) provides
preliminary evidence that decreased amplitude and robustness of
the circadian sleep-wake rhythm precedes MCI and is associated
with increased risk of MCI and conversion to dementia. The
study used actigraphy to assess baseline circadian sleep-wake
rhythms in 1282 healthy community-dwelling women whose
average age was 83 years. Cognitive function was assessed at
baseline using the MMSE and again with more comprehensive
measures at follow-up almost 5 years later, on average. Their
findings—circadian dysregulation preceded MCI and increased
risk of AD conversion—are very intriguing; so much so that
they were highlighted for review in “Critically Appraised Top-
ics” (Schlosser Covell et al., 2012). Regrettably this study has
significant methodological limitations, as discussed in Schlosser
Covell et al. (2012): (1) participants with baseline MMSE score
>24 were deemed cognitively normal, but scores of 24–27 can
meet criteria for MCI, which may have led to overestimating
conversion rates; and (2) only 3 days of actigraphy were used to
assess circadian sleep-wake rhythms, which is insufficient given
the variability inherent in actigraphic recordings. As such, further
studies are required to explore the relationship between circa-
dian regulation of sleep-wake rhythms, MCI, and its conversion
to AD.
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Mild cognitive impairment and dementia are heteroge-
neous and thus it makes intuitive sense that associated sleep
disruptions—and the benefits of sleep interventions—would vary
as a function of etiology. Presumably, sleep interventions would
have greatest effect in individuals most likely to develop AD-
related neuropathology of the circadian system, assuming inter-
vention is possible early in the disease process. As such, MCI
may be useful to identify individuals who are at higher risk
of developing dementia—by age-matched comparison; however,
scarce resources would be better utilized if we could stratify risk of
conversion from MCI to AD-type dementia. The National Insti-
tute on Aging—Alzheimer’s Association (NIA-AA) has proposed
criteria to define an AD spectrum within MCI using specific
biomarkers associated with AD (i.e., valid indicators of Aβ deposi-
tion and neuronal injury; Albert et al., 2011). We suggest research
priority should focus on identification, testing, refinement, and
implementation of chronotherapeutic interventions—targeting
older adults with MCI—with an emphasis on individuals most
likely to convert to AD-type dementia (i.e., individuals with a-
MCI and AD associated biomarkers/genotype).
CONCLUSION
Without discovery of a cure or interventions that delay disease
progression, dementia’s annual worldwide economic impact is
expected to surpass $1 trillion USD as early as 2030. A cure for
dementia—if one is possible—is likely many years away. Thus,
a research imperative is to reduce dementia’s economic impact
through interventions that promote cognitive function, preserve
capacity for independent living, and delay need for institutional
care. We argue that disrupted circadian sleep-wake rhythms in
AD are of particular importance, given their impact on cognitive
function. Sleep consolidation and duration change as a function
of normal aging. However in AD—by comparison—disruptions
of circadian sleep-wake rhythms are exaggerated. These disrup-
tions become extreme as AD progresses from moderate to severe.
In addition to their potential to accelerate cognitive decline,
AD-related sleep disruptions greatly increase caregiver burden;
which is a primary trigger in the decision to transition from
community dwelling to institutional care. By improving sleep in
AD, chronotherapeutic interventions might reduce the burden of
AD—thereby buying time for the discovery of a cure. Because
light is the most potent chronobiotic, BLT may have the greatest
potential for use in AD. Alas, results of RCTs using BLT have
been highly variable and effects are at best modest. However, to
date, there have been too few RCTs to draw definitive conclusions.
Furthermore, we discussed several methodological issues that
could explain the disappointing results so far. As such, we believe
the science examining chronotherapy for use in AD remains in its
infancy.
WHERE WE NEED TO GO: A ROAD MAP FOR FUTURE TRIALS
Defining populations at high Alzheimer’s disease-risk
By itself MCI may be far from ideal as a near-term indicator
of conversion to AD—lacking sensitivity and specificity as oper-
ationally defined to date—however, when used in combination
with biomarkers of Aβ deposition and neuronal injury there may
be greater potential to stratify AD risk. If future RCTs are to
accurately assess MCI interventions, it is imperative that studies
recognize this heterogeneity by employing stratified designs that
identify an intervention’s differential effects across the NIA-AA’s
Uncertain, Intermediate, and High classifications for probability of
MCI due to AD. Furthermore, under this MCI umbrella—in com-
bination with biomarkers that differentiate AD risk—key “at risk”
sub-populations warrant research priority in future RCTs: (1)
individuals with the APOE-ε4 genotype; and (2) individuals with
comorbid conditions including diabetes, cardiovascular disease,
and stroke. Presumably, regulation of circadian rhythms and sleep
will be differentially impaired across these sub-populations, and
thus, chronotherapy should be assessed for each sub-population
independently.
Chronotherapy to protect sleep and preserve cognitive function
Bright Light Therapy—brighter, bluer, and for longer. To date,
there have been too few RCTs testing BLT in older adults with
dementia to come to any conclusions regarding its potential to
improve sleep quality in this important population. The duration
and intensity of BLT typically employed by these RCT’s—while
shown to be effective in healthy young adults—may not have
been sufficient to enhance circadian regulation for older adults,
perhaps due to age-related changes in light perception and within
the SCN itself. We recommend testing brighter light intensities for
longer durations, and where possible blue-enriched light should
be used. Furthermore, BLT needs to be tested in community
dwelling MCI populations to determine if early intervention
would have greater efficacy than has been shown previously in
institutionalized AD patients.
With regard to timing of BLT, we suggest RCTs are needed to
independently assess three distinct approaches: (1) early morning
light; (2) all day bright light; and (3) evening light. Early morning
light for as long as is practical should promote enhanced circadian
regulation by providing a strong, consistent entrainment signal
for an aging biological clock. Note that avoiding nighttime light
is equally important in order to avoid conflicting signals. As
such—for BLT to be effective—the priority is to hit the biological
clock with a strong, unambiguous demarcation between day and
night.
Increasingly limited exposure to bright light during the day
is a consequence of the relatively sedentary lifestyle typical of
advanced age—decreased daytime light exposure is particularly
problematic in nursing homes (Campbell et al., 1988; Shochat
et al., 2000). This decreased exposure to daytime light may
contribute to age-related amplitude suppression of melatonin
secretion at night: bright light during the day has been shown
to increase melatonin amplitude at night (Park and Tokura,
1999); whereas dim light (i.e., <200 lux) at night dramatically
suppresses melatonin secretion (Gooley et al., 2011). Thus, age-
related decreased melatonin amplitude could be related to lower
daytime light exposure and more nocturnal light exposure (e.g.,
getting up to go to the bathroom; watching TV or reading late at
night when one cannot sleep).
Melatonin amplitude at night is correlated with sleep quality
and duration (Morris et al., 1990; Pandi-Perumal et al., 2005),
so decreased nocturnal melatonin might be a contributing factor
in age-related sleep disruptions. Therefore, RCTs testing all day
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FIGURE 2 | A simplified schematic of the proposed interventions that
may have potential to delay AD pathogenesis. The green arrows indicate
pathways for improved circadian regulation and sleep quality, ultimately
delaying AD pathogenesis. According to this model, chronobiotics (i.e.,
bright light therapy (BLT); melatonin; exercise; and food restriction) and
good sleep hygiene could be used individually—but preferably in
combination—to improve circadian regulation and sleep quality, decrease
inflammation and Aβ deposition, and thereby delay AD pathogenesis.
bright light, as used in Riemersma-van der Lek et al. (2008)—but
with brighter, blue-enriched light, aimed at increasing melatonin
amplitude and increasing sleep duration—would be informative.
Finally, evening light (i.e., BLT coordinated with the beginning of
the wake-maintenance zone, but well before habitual sleep onset)
may be useful in two ways: first, it might enhance functioning
of the wake-maintenance zone; and secondly, it may help extend
sleep duration by delaying Tb-min.
Melatonin—at bedtime in combination with Bright Light
Therapy. In addition to its well characterized chronobiotic prop-
erties (Arendt and Skene, 2005), melatonin has recently become a
research priority for its anti-oxidant properties including reduced
inflammation due to oxidative stress (Reiter et al., 2000) and its
potential for combating cancer progression (Margheri et al., 2012;
Sánchez-Hidalgo et al., 2012). As such—if possible—reversing
age-related reduced amplitude of nocturnal melatonin secretion
(Burgess and Fogg, 2008) may be important for improving not
only sleep, but general health in older adults as well. Melatonin
supplements (2.5 mg) taken orally at night—by itself or in com-
bination with all day BLT—can improve sleep in nursing home
residents; but by itself negative side-effects on affect and behavior
were observed (Riemersma-van der Lek et al., 2008). Therefore—
at least when used in older adults with AD—low-dose melatonin
should be used in combination with BLT. Furthermore, the long-
term effects of melatonin supplements have yet to be determined,
and thus, additional study is warranted. As an alternative, dietary
sources such as tart cherry juice have recently been shown to
increase nocturnal melatonin levels and enhance sleep quality
(Howatson et al., 2012).
Exercise and social engagement—is anytime a good time? Exer-
cise is an effective intervention that promotes cognitive function
and neural plasticity in MCI populations (Lautenschlager et al.,
2008; Baker et al., 2010; Nagamatsu et al., 2012, 2013); however,
the mechanisms involved have yet to be explained. Exercise has
long been associated with better sleep—and given the importance
of sleep for cognitive function—it remains possible that improved
sleep is an underlying mechanism by which exercise promotes
cognitive function in MCI. Future RCTs of exercise effects on
cognitive function that also include quantitative measures of
sleep (e.g., actigraphy or EEG) would be informative. Given that
exercise trials to date have typically used exercise sessions 2–3
days/week, we suspect improved cognitive performance observed
in previous exercise trials has been the result of mechanisms
separate and distinct from improved circadian regulation. We
expect regularly scheduled daily exercise—or at least every other
day—would be necessary to have chronobiotic effects. That being
said, it may be possible to enhance efficacy of exercise interven-
tions by increasing frequency to add chronobiotic effects and
improved circadian regulation—which may result in synergies
that further improve sleep quality and cognitive function in
MCI. Furthermore, studies are needed to confirm exercise effects
vary in a time dependent manner, in the same way that light
does.
A combined approach to chronotherapy is best practice. If
improved circadian regulation in older adults at high AD risk is
the objective, we wish to emphasize the importance of under-
standing how our biological clock processes time cues. The SCN
has evolved intricate pathways capable of integrating diverse
time cues (i.e., light, activity, mealtime, and social), enhanc-
ing precision of entrainment to the environment in which we
live. Given age-related weakened circadian regulation—which
is exaggerated in AD and perhaps in MCI—it makes intuitive
sense that combining BLT, melatonin, exercise, food restric-
tion, and improved sleep hygiene would have greatest effect.
We hypothesize that for individuals at high AD-risk, regula-
tion of circadian rhythms and sleep will be best improved
by a combined, coordinated chronotherapeutic approach that
employs daily BLT and exercise—in the morning and again in the
evening—with low-dose melatonin supplements at night before
bed, and regularly scheduled mealtimes (i.e., breakfast, lunch,
and dinner while avoiding large meals at night that suppress
melatonin).
While we fully understand the need to test intervention com-
ponents independently, we believe equal importance should be
placed on assessing the potential for synergistic effects when
chronobiotics are used in a coordinated fashion. Similarly, using
the neuroinflammatory perspective of AD as an example, we
believe it makes sense to employ multifactorial approaches—
combining known anti-inflammatory factors—when develop-
ing and testing potential interventions (see Figure 2 for a
schematic outlining the proposed interventions with poten-
tial to combat AD pathogenesis). As such lifestyle interven-
tions that target improved diet, increased exercise, improved
sleep hygiene, and chronotherapy would seem to provide our
best option to identify an effective intervention—compared
with a singular focus aimed at determining independent effi-
cacy of any of these factors individually. Given the frighten-
ing economic impact and human costs associated with AD,
we argue that our highest priority should first be to identify
an approach that works—combining all of the tools at our
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disposal—and only after we have done so, should we turn our
focus to dissecting the independent mechanisms underlying that
success.
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